TY - JOUR
T1 - Chemotherapy in advanced pancreatic adenosquamous carcinoma
T2 - A retrospective multicenter AGEO study
AU - Auvray Kuentz, Marie
AU - Hautefeuille, Vincent
AU - de Mestier, Louis
AU - Coutzac, Clélia
AU - Lecomte, Thierry
AU - Nardon, Victor
AU - Artru, Pascal
AU - Turpin, Anthony
AU - Drouillard, Antoine
AU - Malka, David
AU - Tran-Minh, My Linh
AU - Trouilloud, Isabelle
AU - Lièvre, Astrid
AU - Williet, Nicolas
AU - Pernot, Simon
AU - Touchefeu, Yann
AU - Taieb, Julien
AU - Hammel, Pascal
AU - Zaanan, Aziz
N1 - Publisher Copyright:
© 2022 UICC.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Pancreatic adenosquamous carcinoma (PASC) account for <5% of pancreatic malignancies. The efficacy of modern chemotherapy regimens in patients with advanced PASC is unknown. Patients with advanced PASC from 2008 to 2021 were consecutively included in this retrospective multicenter study. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier method. Ninety-four PASC from 16 French centers were included (median age, 67.3 years; males, 56.4%; metastatic disease, 85.1%). The first-line treatment was chemotherapy for 79 patients (84.0%) (37 FOLFIRINOX (FX), 7 Gemcitabine-nab paclitaxel (GN) and 35 for all other regimen) or best supportive care (BSC) alone for 15 patients (16.0%). No significant difference was observed between FX and GN in terms of PFS (P =.67) or OS (P =.5). Modern regimens pooled together (FX and GN) as compared to all others chemotherapy regimens showed an improvement of overall response rate (39.5% and 9.7%, P =.002), PFS (median, 7.8 vs 4.7 months, P =.02) and OS (median, 12.7 vs 9.2 months, P =.35). This large study evaluating first-line treatment regimens in advanced PASC suggests that modern regimens as FX or GN may be preferable to all other chemotherapy regimens. These results deserve confirmation in prospective studies.
AB - Pancreatic adenosquamous carcinoma (PASC) account for <5% of pancreatic malignancies. The efficacy of modern chemotherapy regimens in patients with advanced PASC is unknown. Patients with advanced PASC from 2008 to 2021 were consecutively included in this retrospective multicenter study. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier method. Ninety-four PASC from 16 French centers were included (median age, 67.3 years; males, 56.4%; metastatic disease, 85.1%). The first-line treatment was chemotherapy for 79 patients (84.0%) (37 FOLFIRINOX (FX), 7 Gemcitabine-nab paclitaxel (GN) and 35 for all other regimen) or best supportive care (BSC) alone for 15 patients (16.0%). No significant difference was observed between FX and GN in terms of PFS (P =.67) or OS (P =.5). Modern regimens pooled together (FX and GN) as compared to all others chemotherapy regimens showed an improvement of overall response rate (39.5% and 9.7%, P =.002), PFS (median, 7.8 vs 4.7 months, P =.02) and OS (median, 12.7 vs 9.2 months, P =.35). This large study evaluating first-line treatment regimens in advanced PASC suggests that modern regimens as FX or GN may be preferable to all other chemotherapy regimens. These results deserve confirmation in prospective studies.
KW - adenosquamous carcinoma
KW - advanced disease
KW - chemotherapy
KW - pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85145596851&partnerID=8YFLogxK
U2 - 10.1002/ijc.34414
DO - 10.1002/ijc.34414
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36562310
AN - SCOPUS:85145596851
SN - 0020-7136
VL - 152
SP - 1894
EP - 1902
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 9
ER -
